http://www.latimes.com/news/science/la-sci-hormone5mar05,0,5953563.story"
Three years after they stopped hormone replacement therapy, women who took the drugs still had a 27% higher risk of developing breast cancer than those wo took a placebo, researchers reported today.The women were participants in the Women's Health Initiative, halted abruptly in 2002 when researchers found that the doses of estrogen and progestin increased patients' risk for heart disease, stroke and breast cancer.
Related
- Breast cancer risks
Related Stories
- Hormone therapy is all in the timing
- Profiling the suspect
- Suspects, but not all perps
- Red meat may boost cancer risk
Although the heart risks eased after the women stopped taking the drugs, their overall cancer risk remained 24% above average.
"Menopausal women really need to think through whether using estrogen-progestin is the right thing to do, particularly if continued for more than a few years," said Marcia L. Stefanick, a professor of medicine at Stanford University and one of the authors of the paper appearing in the Journal of the American Medical Assn.
Physicians taking the medical history of a new patient past menopausal age should also "ask specific questions about past use of hormone therapy" and be alert for possible problems, said Dr. Robert W. Rebar, executive director of the American Society for Reproductive Medicine, who was not involved in the study.
"The important message is women really need to make sure they continue getting their mammograms," Stefanick said.
Some experts noted that hormone use has changed dramatically since 2002, with physicians prescribing lower doses for shorter periods of time. They are also giving the drugs to younger women -- a group that the Women's Health Initiative found was less likely to suffer adverse effects from the therapy.
"We really don't believe this latest article provides any new guidance," said Dr. Gary Stiles, chief medical officer of Wyeth Pharmaceuticals, which manufactures the Prempro used in the study. "We continue to recommend that it be used at the lowest effective dose for the shortest duration of time possible."
"
